Specialized Resource B- Gene Transfer and Cell Engineering (SR-B). SR-B of ICMIC-3 will support preclinical and clinical gene transfer studies in RP1. It also provides support for engineering tumor cell lines for studies by RP2 and RP4. These projects are highly dependent on achieving efficient gene transfer in either primary T lymphocytes, packaging cell lines or tumor cell lines. In research and pre-clinical studies, the SR-B assists Investigators in the;1. Construction of recombinant oncoretroviral and lentiviral vectors 2. Transfection or transduction of vector in packaging cells and selection of producer cell lines 3. Characterization of vector transmission and stability 4. Expansion of packaging cell clones and identification of the best clone for the intended target cells 5. Titration of cell-free retroviral stocks 6. Detection of replication-competent retrovirus in viral stocks and transduced target cells 7. Detection of oncoretroviral and lentiviral vector integration sites by LM-PCR 8. Optimization of tumor cell lines and T lymphocyte transduction with retroviral vectors 9. Optimization of lymphocyte expansion ex vivo with Dynabeads? ClinExvivoCD3/CD28. In the clinical phase, the SR-B will carry out and/or coordinate the: 1. Generation of high-titer producer cell clones, master cell banks (MCB) and retroviral stocks for clinical studies 2. Production of clinical viral stocks 3. Expansion and transduction of patient cells in semi-closed systems in collaboration with the investigators of the clinical trial 4. Detection of RCR and other biosafety testing in cultured packaging cell clones (MCB), viral stocks and clinical specimens 5. Characterization of the expression of the transgene (imaging reporters or PSMA-CAR) by either RT-PCR or flow cytometry analysis in transduced patient cells 6. Determination of the vector copy number by Real time PCR in the peripheral blood, bone marrow samples and available tissues of the patients at different time points after infusion of the genetically modified T cells.

Public Health Relevance

This Specialized Resource will provide services and expertise in gene transfer, molecular analysis and cellular processes to Research Projects 1, 2 and 4. Through SR-B, the centralized generation of high-quality producer cell lines, of viral stocks and the development of procedures to efficiently engineer tumor cell lines and transduce patients T cells will permit standardization of procedures and facilitate the exchange of information, reagents and expertise between all the projects. It will also be cost effective.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086438-14
Application #
8725590
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
14
Fiscal Year
2014
Total Cost
$192,940
Indirect Cost
$87,378
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Rodina, Anna; Wang, Tai; Yan, Pengrong et al. (2016) The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 538:397-401
Lee, Sang-Gyu; Gangangari, Kishore; Kalidindi, Teja Muralidhar et al. (2016) Copper-64 labeled liposomes for imaging bone marrow. Nucl Med Biol 43:781-787
Demoin, Dustin Wayne; Shindo, Masahiro; Zhang, Hanwen et al. (2016) Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. Nucl Med Biol 43:606-11
Arevalo-Perez, Julio; Paris, Manuel; Graham, Michael M et al. (2016) A Perspective of the Future of Nuclear Medicine Training and Certification. Semin Nucl Med 46:88-96
Cheal, Sarah M; Xu, Hong; Guo, Hong-Fen et al. (2016) Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging 43:925-37
Wang, Xiuyan; Rivière, Isabelle (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015
Cherkassky, Leonid; Morello, Aurore; Villena-Vargas, Jonathan et al. (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126:3130-44
Kadota, Kyuichi; Sima, Camelia S; Arcila, Maria E et al. (2016) KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Am J Surg Pathol 40:1579-1590
Mayor, Marissa; Yang, Neng; Sterman, Daniel et al. (2016) Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 49:1324-33
Adusumilli, Prasad S (2016) Spread through alveolar spaces: An aerogenous invasion in pulmonary adenocarcinomas. J Thorac Cardiovasc Surg 152:73-4

Showing the most recent 10 out of 177 publications